echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Immunogen and Takeda pharmaceutical reached a $440 million ADC cooperation agreement

    Immunogen and Takeda pharmaceutical reached a $440 million ADC cooperation agreement

    • Last Update: 2015-03-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Biovalley, March 24, 2015, after a long silence, immunogen, a famous pharmaceutical company, finally received another major good The company announced a cooperation agreement with Japanese pharmaceutical giant Takeda pharmaceutical company on antibody drug coupling technology, with a total value of about 440 million US dollars This is also the first significant good news after the company's self-developed ADC technology suffered a clinical phase III failure last year, which will undoubtedly greatly improve the confidence of investors and the market in immunogen According to the agreement, Takeda pharmaceutical will pay US $20 million in advance In return, immunogen will license its ADC technology to Takeda pharmaceutical for the development of two tumor target drugs (specific targets are not disclosed in the news), and the milestone bonus for each target will be as much as US $210 million Takeda will be responsible for the later research and development, marketing and other work of the two drugs In the future, immunogen will share the copyright of these two drugs Once the agreement goes smoothly, Takeda pharmaceutical has the right to add a target drug research as the case may be This cooperation agreement with Takeda pharmaceutical brings more than $100 million to immunogen Last year, kadcyla, which was jointly developed by the company and Roche, was defeated in the clinical phase III experiment of breast cancer treatment, which caused widespread doubts on its ADC technology in the market Now, Takeda's participation will undoubtedly dispel such doubts to a large extent Christopher Claiborne, director of Takeda's tumor drug research and development department, said in a statement that immunogen's ADC technology will enrich the company's strength in the field of tumor research and development, showing strong confidence in ADC technology In fact, ADC technology has experienced several ups and downs since its inception The researchers believe that coupling the drug with tumor specific antibodies will help increase the tumor killing ability of the drug and reduce its side effects This technology has also won the recognition of most giants in the industry Immunogen has reached extensive cooperation agreements with Amgen, Lilly, Roche, Novartis and Sanofi.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.